Velzatinib receives orphan drug designation in Japan for GIST
Posted on November 22, 2026
GSK has received Orphan Drug Designation in Japan for velzatinib as a potential treatment for gastrointestinal stromal tumour.
Japan’s Ministry of Health, Labour and Welfare granted the designation based on data from the ongoing Phase I/Ib StrateGIST 1 study in patients with advanced GIST.
GSK said the early-stage trial has shown promising anti-tumour activity alongside a favourable tolerability profile.
Velzatinib is a highly selective KIT inhibitor being developed specifically for gastrointestinal stromal tumour.
The drug is designed to target clinically relevant primary and key secondary KIT mutations, which can contribute to treatment resistance in GIST.
Around 80% of GIST cases are driven by mutations in the KIT gene, most commonly involving primary mutations in exons 9 and 11.
GSK said approximately 90% of patients receiving first-line treatment eventually develop additional KIT resistance mutations, including mutations in exons 13 and 17.
The company is accelerating development of velzatinib across both first- and second-line advanced or metastatic GIST.
Phase III studies are currently underway in both settings.
GSK said enrolment in the second-line study is progressing ahead of schedule, with data expected in the second half of 2027.
Velzatinib has also received Fast Track designation from the U.S. Food and Drug Administration, as well as Orphan Drug Designations in the U.S. and European Union.
Additional clinical and translational data are being presented at the 2026 Connective Tissue Oncology Society Annual Meeting in Seoul.
Seven abstracts are expected to cover velzatinib, including analyses of clinical activity by KIT mutation, preclinical research into mutation coverage and biomarker studies.
GSK is also conducting the Phase II StrateGIST J study in Japan.
The study is evaluating velzatinib in patients whose GIST has progressed following available therapies or who are unable to tolerate existing treatment options.
GIST is a rare cancer that most commonly develops in the stomach or small intestine.
Globally, an estimated 80,000 to 120,000 people are diagnosed with the disease each year.
In Japan, the age-adjusted annual incidence is estimated at approximately four cases per 100,000 people.
Despite improvements in treatment over the past two decades, outcomes remain poorer once GIST has spread to other parts of the body.
Related Topics and Keywords
Biopharma, clinical trials, drug resistance, fda fast track, gastrointestinal stromal tumour, GIST, GSK, Japan, KIT inhibitor, KIT mutation, MHLW, Oncology, orphan drug designation, pharma news, Phase I, Phase II, phase III, rare cancer, StrateGIST 1, StrateGIST J, targeted therapy, TKI, Tyrosine Kinase Inhibitor, velzatinib
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy















